Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Japan Approves AbbVie’s Aquipta, Novo’s IcoSema, Pfizer’s Tukysa, and More
Japan granted regulatory approvals for a batch of new medicines and label expansions on February 19 including AbbVie’s migraine therapy Aquipta (atogepant) and Novo Nordisk’s once-weekly insulin-GLP-1 combo Kyinsu (insulin icodec + semaglutide), otherwise known as IcoSema. The Ministry of…
To read the full story
Related Article
- Japan OKs Listing of Ambelvist, Dojolvi, Sohonos, and Finally Inrebic
May 14, 2026
- Voranigo and More Meds Missing from April Listing Slate; Servier Plans Packaging Change
April 10, 2026
- Japan OKs Listing of Exdensur, Aquipta, Tukysa, and More; New Price Rules Applied to Two
April 9, 2026
- Japan Panel Green-Lights Pfizer’s Tukysa, Wider Labels for Tezspire, and More Drugs
January 30, 2026
- Japan Panel OKs AbbVie’s Aquipta, Ipsen’s Sohonos, and Novo’s IcoSema for Approval
January 26, 2026
REGULATORY
- Japan Panel to Review Brinsupri, Hyrnuo, Inlexzo, GSK’s Hep B Med on July 27
July 14, 2026
- CEA Review Group Debates Comparator Technologies, ICER Uncertainty
July 14, 2026
- MHLW Urges Stakeholders to Define Essential LLP Information
July 14, 2026
- Japan to Set Up Subgroup to Flesh Out Pharma Investment Roadmap: PM
July 13, 2026
- Immunization Act Revision Faces Uncertain Fate as Diet Clock Ticks Down
July 13, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…